Clinical trial · no report yet · Phase 1/Phase 2
ERADICATE
ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
- NCT07198724 ↗
- Recruiting
- Kristina A. Fanucci
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Bluesky threads | 2 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Metastatic Breast Cancer; HER2 Low Breast Carcinoma; HER2-negative Breast Cancer; Breast Cancer; Breast Cancer Female
- Interventions
- Elacestrant; Trastuzumab Deruxtecan
- Arms
- Phase 1b: Elacestrant + Trastuzumab Deruxtecan · Experimental
- Phase 2: Elacestrant + Trastuzumab Deruxtecan · Experimental
- Enrollment
- 65 (estimated)
- Primary outcomes
- Recommended phase II dose (RP2D)
- Objective Response Rate (ORR)
- Sponsor
- Kristina A. Fanucci with Stemline Therapeutics, Inc.
- Start
- Nov 17, 2025
- Primary completion
- Jun 1, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT07198724 · updated Jun 10, 2026